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Cultured human retinal pigment epithelial cells (RPE) secrete insulin-like growth 
factor binding proteins (IGFBPs), a family of polypeptides which modulate the 
actions of the insulin-like growth factors. RPE cells secrete two ICFBPs with Mr 
estimates of 34,000 and 46,000, respectively. Treatment of RPE cells with IGF-I 
markedly stimulated the secretion of the 46,000 Mr form. This stimulation oc- 
curred via an IGF-I receptor independent mechanism because both [QAYLIIGF-I 
(an IGF-I analogue with decreased affinity for the IGFBPs but normal affinity for 
the IGF-I receptor) and d R 3  (a blocking monoclonal antibody against the IGF-I 
receptor) had no effect on IGF-I stimulated increases in IGFBPs. Additionally, 
IQAYLIIGF-I enhanced RPE cell proliferation to the same magnitude as IGF-I. 
Treatment with IGF-I, [QAYLIIGF-I, or a-IR, had no effect on steady-state levels of 
the 2.5 kb IGFBP-3 or the 1.3 kb IGFBP-6 mRNA transcripts as measured by 
Northern blotting and quantitative autoradiography. Forskolin and a group of 
candidate growth factors, including platelet-derived growth factor, epidermal 
growth factor, and acidic and basic fibroblast growth factor, modestly increased 
ICFBP secretion when compared to untreated cells, but these effects were small 
when compared to IGF-I treatment. Fetal calf serum enhanced the presence of the 
2.5 kb ICFBP-3 mRNA transcript in a dose-dependent fashion but had no effect on 
the 1.3 kb IGFBP-6 mRNA transcript. IGF-I, forskolin, and the candidate growth 
factors had no effect on either ICFBP-3 or IGFBP-6 mRNA. These data suggest that 
the production of IGFBPs in human RPE cells i s  regulated by distinct mechanisms 
which include (1)  an IGF-I receptor independent interaction of IGF-I with secreted 
IGFBPs and (2 )  de novo synthesis of IGFBPs by serum-containing factors. 
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Insulin-like growth factors I and I1 (IGF-I and -11) are 
polypeptides which play a n  important role in cellular 
growth and differentiation (Sara and Hall, 1990). The 
actions of IGF-I and -11 are modulated, in part, by a 
family of structurally related proteins, the insulin-like 
growth factor binding proteins (IGFBPs) (Sara and 
Hall, 1990; Clemmons, 1991a). Six distinct IGFBPs 
have been identified and cloned (Clemmons, 1991a; 
Drop, 1992). These IGFBPs transport IGFs (Binoux 
et al., 1991), modulate IGF tissue availability (Clem- 
mons, 1991b), and alter IGF receptor binding (Mc- 
Cusker et al., 1991a). IGFBP expression varies by cell 
type (Clemmons, 1991a; Drop, 1992) and is regulated 
not only by nutritional status (Clemmons and Under- 
wood, 1991; Mc Cusker et al., 1991b) but also by hor- 
mones (Ooi e t  al., 1990; Torring et al., 1991; Unterman 
et al., 1991) and growth factors (Barreca et al., 1992; 
Corps and Brown, 1991; Loret et al., 1991; Martin and 
Baxter, 19911, especially IGF-I (Martin et al., 199213; 
Conover, 1991; Clemmons, 1991a). In vivo, IGF-I in- 
creases serum levels of IGFBP-2 (Clemmons, 1991a,b) 
and mediates growth hormone coupled increases in 
IGFBP-3 (Clemmons and Underwood, 1991). In vitro 
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IGF-I enhances the levels of IGFBPs, particularly 
IGFBP-3, in cultured fibroblasts (Bale and Conover, 
19921, myocytes (McCusker and Clemmons, 1988), and 
osteoblasts (Schmid et al., 1989). 
Growth factor mediated increases in IGFBPs may be 
an  important determinant in the growth and mainte- 
nance of tissues (Corps and Brown, 1991; Loret et al., 
1991). IGFBPs contain an  Arg-Gly-Asp sequence near 
their carboxyl termini (Clemmons, 1991b) which is re- 
quired for cellular attachment of matrix proteins. By 
binding to extracellular surfaces, secreted IGFBPs 
could target IGFs to specific cell types, increasing the 
local bioavailability of IGFs to these cells. Indeed, in 
fibroblasts, IGF-I action is augmented by incubation 
with IGFBP-3, implying a direct interaction of exoge- 
neous IGFBP-3 with the cell surface (Conover, 1992). 
As an  initial approach towards understanding 
growth factor regulation of IGFBP function, we exam- 
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ined the regulation of IGFBP gene and protein expres- 
sion in human retinal pigment epithelial (RPE) cells. 
RPE cells provide a good in vitro model system for ex- 
amining growth factor regulation of IGFBP production 
(Waldbillig et al., 1991, 1992). Cultured human RPE 
cells express IGFBP-3 and IGFBP-6 mRNA and secrete 
two IGFBPs with estimated molecular weights of 
46,000 and 34,000 (Randolph et al., 1993). These cells 
synthesize mRNA for the type I and type I1 IGF recep- 
tors (Martin et al., 1991) and display an  IGF-I mediated 
increase in DNA synthesis (Leschey et al., 1990). It has 
been suggested that epithelial secretion of IGFBPs may 
allow targeting of IGFs to epithelial cells with concom- 
itant growth (Clemmons, 1991a; Laron et  al., 1991). 
In the present study, we examined the relative roles 
of serum, IGF-I, and other growth factors in the regula- 
tion of human RPE IGFBP-3 and IGFBP-6 mRNA and 
protein. We present evidence that serum, but not IGF-I, 
regulates IGFBP-3 mRNA expression while IGF-I, but 
not other growth factors, increases IGFBP-3 protein via 
a receptor independent mechanism. 
MATERIALS AND METHODS 
Chemicals 
Minimum essential medium (MEM), Hank's bal- 
anced salt solution, trypsin-EDTA, PDGF, and basic 
FGF were obtained from Grand Island Biological 
(Grand Island, NY). Insulin and forskolin were pur- 
chased from Sigma (St. Louis, MO), EGF and acidic 
FGF from Bachem (Torrence, CAI. IGF was purchased 
from BioSource International (Camarillo, CAI and 
des (1-3)IGF-I from GroPep (Adelaide, Australia). 
[Gln3Ala4Tyr1sLeu161 IGF-I(IQAYL1IGF-I) was a gift 
from Dr. Margaret A. Cascieri, Merck, Sharp and 
Dohme Research Laboratories (Princeton, NJ). IGF-I 
receptor antibody (a-IRJ was obtained from Oncogene 
Science (Uniondale, NY). Bovine calf serum was pur- 
chased from Hyclone Labs (Logan, UT). All tissue cul- 
ture supplies were from Costar (Cambridge, MA) and 
Corning Glass Works (Corning, NY). Restriction en- 
zymes were purchased from Bethesda Research Labora- 
tories (Gaithersburg, MD). Molecular biology grade re- 
agents were obtained from Sigma, and remaining 
chemicals were of reagent grade and purchased from 
Baker Chemical (Phillipsburg, NJ) or Fisher Scientific 
(Fairlawn, NJ). 
Cell culture 
Retinal pigment epithelia were isolated from human 
postmortem eyes obtained from the Michigan Eye 
Bank. Primary RPE cell cultures were established 
and maintained as previously described (Feldman 
et al., 1991). Cells were subcultured at a density of 
1.5-2 x lo6 cells per 75 cm2 culture flask in MEM con- 
taining 20% CS and grown at 37°C in a humidified 95% 
air-5% CO, atmosphere. The medium was changed 
three times weekly. Experiments were performed on 
passage numbers 10-20 of RPE cell lines established 
from two separate patients. Prior to dosing, cells were 
rinsed three times in serum free MEM, followed by 
an incubation at 37°C in 10 ml serum free MEM for 
1.5-2 h. 
Cell proliferation assay 
Cells were plated at a density of 6 x lo4 cells/cm2 in 
96-well plates in 100 p1 MEM with or without IGF-I, 
des(1-3) IGF-I or [QAYLIIGF-I. Cell proliferation was 
measured using the MTT colorimetric assay (Hansen 
et al., 1989). MTT (3,(4,5-dimethylthiazol-z-y1)2,5- 
diphenyltetrazolium bromide) (25 pi) was added (1 mg/ 
ml) for a 2 h incubation at 37°C in a humidified atmo- 
sphere with 5% CO, followed by an  overnight 
incubation in 100 pl lysis buffer (50% N,N-dimethyl 
formamide, 20% w/v SDS, pH 4.7). The optical density 
(OD) of each well was measured at a wavelength of 570 
nm by a Bio-Rad Model 2550 EIA reader (Bio-Rad Lab- 
oratories, Melville, NY). 
Northern analysis 
Total cellular RNA was isolated from cells using the 
guanidinium thiocyanate-phenol extraction (Chom- 
czynski and Sacchi, 1987). Northern analysis was per- 
formed as previously reported (Schmallbruch, 1991; 
Martin et al., 1992a). Membranes were hybridized with 
"P-dCTP labelled (1-10 x 10' cpdrng) cDNA probes 
for human IGFBP-3 (535 bases excised with Hind 111 
and EcoRI), human IGFBP-6, (267 bases excised with 
PstI) (Yee et al., 19911, and chicken p-actin (2.1 kb 
excisted with PstI) (Cleveland et al., 1980). For each 
hybridization, OD values were measured densitometri- 
cally by averaging multiple exposures in the linear 
range of the film. Each experimental and p-actin OD 
value was expressed as a percentage of the untreated 
control value. Relative OD values were obtained by 
dividing the experimental OD by the respective p-actin 
(%I. 
Western ligand blotting 
In some experiments, conditioned medium was ob- 
tained and concentrated twentyfold using a Centriprep 
concentrator (Amicon, Beverly, MA) with a 10,000 Dal- 
ton molecular weight cutoff. The protein content of the 
concentrates was determined using the Bio-Rad DC 
Protein Assay (Bio-Rad, Richmond CAI. Protein (25 kg) 
in 35-50 pl of concentrated media and an  equal volume 
of two times concentrated sample buffer (0.1 M Tris- 
HC1, pH 6.4, 4% sodium dodecyl sulfate (SDS), 0.2% 
bromophenol blue, 20% glycerol) was boiled for 3 m, 
loaded into a 3% acrylamide stacking gel, and electro- 
phoresed through a 10% polyacrylamide resolving gel 
a t  200-300 V under nonreducing conditions. Rainbow 
molecular weight standards (Amersham, Arlington 
Heights, IL) were used to assess relative molecular 
weights. Proteins were transferred to nitrocellulose 
membranes (0.2 pm) (Schleicher & Schuell, Keene, 
NH) overnight at 20 V in Towbin transfer buffer (0.05 
M Tris, 0.4 M glycine, 0.075% SDS) using a Bio-Rad 
Trans-blot unit (Richmond, CA). Membranes were 
dried at 37°C for 5 m. The following consecutive washes 
in Western ligand blot saline (0.15 M NaC1,O.Ol M Tris 
HC1, pH 7.4) were done at 4°C: 30 m in 3% Nonidet 
P-40, 2 h in 1% bovine serum albumin, and 10 min in 
0.1% Tween 20. Membranes were incubated overnight 
with 1 x lo5 c p d m l  of lZ5IGF-II (Amersham, Arling- 
ton Heights, IL) and 1% BSA, 0.1% Tween 20. After 
rinsing the membranes two times for 15 m at 4°C with 
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Fig. 1. IGFBP profile after IGF-I or IGF-I analogue treatment. RPE 
cells were plated a t  2 x 10" cells/cm2, grown for 7 d in MEM + 20% 
CS, rinsed in MEM as outlined in Materials and Methods and treated 
with either 1 pg/ml a-IR, alone, 3 nM IGF-I, 3 nM des(1-3) IGF-I, or 3 
nM [QAYLIIGF-I f 1 pgiml a-IR,. (A) Western ligand blot of RPE 
conditioned media. 24 h after treatment, immediately prior to RNA 
isolation, conditioned media was collected, concentrated and Western 
ligand blots were performed as outlined in Materials and Methods. 
Molecular weight markers are indicated on the left. 1 pg/ml a-IR, had 
no effect on the 46,000 Mr band in the serum free (SF) control or in the 
presence of IGF-I or IGF-I analogues. 3 nM IGF-I and 3 nM des(1-3) 
IGF-I enhanced the presence of the 46,000 Mr band while 3 nM [QAY- 
LlIGF-I had no effect over that of the SF control. (B) Autoradiograph 
from a Northern blot of IGFBP-3, IGFBP-6 and p-actin mRNA. RNA 
was isolated 24 h after treatment. Northern analysis was performed 
with "P-labeled cDNA probes for IGFBP-3, IGFBP-6 and P-actin, as 
indicated in Materials and Methods. RNA transcript sizes in kb are 
listed at the right of each autoradiograph. Autoradiographs exposed 
for 1 day (IGFBP-31, 2 days (IGFBP-6), and 1 day (p-actin). Densito- 
metric analyses of autoradiographs from multiple exposures of the 
experiments shown in A and at least one additional experiment were 
quantitated using relative OD as described in Materials and Methods. 
There were no differences among treatment groups (data not shown). 
0.1% Tween 20 and two times for 15 m at 4°C in West- IGF-I produced the same pattern of IGFBP band in- 
ern ligand blot saline, membranes were dried in air and tensities as IGF-I. In contrast, treatment with 
exposed to X-Omat film (Eastman Kodak, Rochester, [QAYLIIGF-I reduced the band intensities to the level 
NY) a t  -70°C for 1-7 days in the presence of an  inten- ofuntreated cells (Fig. 1A). Addition ofa-IR,, the block- 
sifying screen. ing antibody against the IGF-I receptor, had no effect 
on the increased intensity of the 46,000 Mr band ob- 
RESULTS 
Effects of IGF-I and IGF-I analogues on IGFBP 
gene and protein expression 
IGF-I can control IGFBP gene and protein expression 
in multiple cell types (Clemmons, 1991a). To initially 
examine the effect of IGF treatment on IGFBP protein 
expression, RPE cell conditioned medium was analyzed 
by Western ligand blotting. Ligand blots of conditioned 
media from cells treated with IGF-I showed increased 
intensity in the 46,000 Mr band (presumed to be 
IGFBPS) when compared to untreated cells (Fig. 1Af. 
To determine if binding of IGF-I to IGFBP-3 was re- 
quired for these effects, cells were treated with IGF-I 
analogues. Des( 1-3)IGF-I has a sixfold increased affin- 
ity for the IGF-I receptor and, at concentrations 31 nM, 
an  equal affinity to IGFBP-3 as IGF-I (Forbes et al., 
1988). [QAYLIIGF-I binds and activates the IGF-I re- 
ceptor with normal affinity but has a 600-fold reduced 
affinity for IGFBP-3 (Cascieri et al., 1991). Des(1-3) 
served after IGF-I or des(f-3)IGF-I treatment (Fig. 1A). 
Northern blots were prepared from RPE cells treated 
for 24 h in serum-free media alone or with the addition 
of 3 nM IGF-I, des(l-3)IGF-I, or LQAYLIIGF-I, in the 
presence or absence of a-IR,. There were no observed 
changes in the 2.5 kb IGFBP-3 transcript or the 1.3 kb 
IGFBP-6 transcript with these treatments (Fig. 1B). 
To examine if changes in cell number were contribut- 
ing to the differences in IGFBP patterns observed with 
Western ligand blotting (although equal amounts of 
protein were electrophoresed for each treatment), cells 
were plated in MEM alone or with the addition of IGF-I, 
des (1-3)IGF-I, or [QAYLIIGF-I. Cell proliferation was 
determined using the MTT assay (Hansen et al., 1989). 
After 48 h, 3 nM IGF-I, des(1-3)IGF-I and [QAYLIIGF-I 
each increased cell number when compared to serum- 
free treatment (21,22, and 30%, respectively); however, 
there were no statistically significant differences in the 
magnitude of the increases between growth factor 
treatments. 
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Serum dependent changes of IGFBP gene and 
protein expression 
Because treatment of cultures with IGF-I did not af- 
fect the abundance of IGFBP-3 mRNA, we speculated 
that other growth factors might potentially modulate 
IGFBP-3 mRNA. As an initial step, we examined the 
effect of increasing concentrations of calf serum on 
IGFBP-3 mRNA production. We reasoned that if serum 
treatment had an effect on IGFBP-3 mRNA, then can- 
didate growth factors, other than IGF-I, might also 
modulate IGFBP-3 mRNA. Serum treatment increased 
the abundance of the 2.5 kb IGFBP-3 transcript in a 
dose-dependent manner with a twofold increase in 
IGFBP-3 mRNA when cells were grown in 20% calf 
serum (Fig. 2). In contrast, there was no effect on 
IGFBP-6 mRNA (Fig. 2). 
We then surveyed the effects of candidate growth 
factors and the CAMP agonist, forskolin, on IGFBP-3 
and -6 gene expression. Insulin, platelet-derived 
growth factor, epidermal growth factor, acidic and basic 
fibroblast growth factor, and forskolin had no effect on 
IGFBP-3 or IGFBP-6 gene expression (Fig. 3). Western 
ligand blots of conditioned media of growth factor 
treated cells revealed the expected 34,000 and 46,000 
Mr proteins (Fig. 4). In two separate experiments, com- 
paring the effects of forskolin, the candidate growth 
factors, and IGF-I on IGFBP secretion, only IGF-I sig- 
nificantly enhanced the presence of the 46,000 Mr pro- 
tein (Fig. 4). Forskolin and the candidate growth fac- 
tors, except for insulin, produced a modest increase in 
the 46,000 Mr protein when compared to untreated 
cells (Fig. 4). 
DISCUSSION 
Cell specific expression of IGFBPs may allow individ- 
ual cell types to influence IGF function in the pericellu- 
lar microenvironment (Clemmons, 1991a,b; Binow 
et al., 1991; Minuto et al., 1991; Rutanen and Pekonen, 
1990). In the current study, we examined growth factor 
regulation of IGFBP gene expression and secretion in 
human RPE cells. We have previously reported that 
human RPE cells express IGFBP-3 and IGFBP-6 
mRNA and secrete two IGFBPs with Mr estimates of 
46,000 and 34,000 (Randolph et al., 1993). The specific 
identities of these IGFBPs have not been determined, 
although we speculate that the 46,000 Mr form repre- 
sents IGFBP-3 and the 34,000 Mr form represents 
IGFBP-6 (based on its Mr and preferential binding of 
IGF-11) (Randolph et al., 1993). 
In the present study, IGF-I had no effect on constitu- 
tive IGFBP-3 or IGFBPS mRNA expression. Similarly, 
the IGF-I analogues, des( 1-3)IGF-I and [QAYLIIGF-I, 
and the IGF-I receptor antibody, a-IR,, did not alter 
IGFBP mRNA expression. These results imply that 
neither sequestration of IGF-I by extracellular IGFBPs 
nor constitutive IGF-I secretion was responsible for the 
lack of an IGF-I effect on IGFBP gene expression. Like 
human RPE cells, cultured bovine kidney epithelial 
cells also express IGFBP-3 mRNA but, unlike RPE 
cells, IGF-I treatment results in a twofold increase in 
IGFBP-3 mRNA (Cohick and Clemmons, 1991). In bo- 
vine fibroblasts, treatment with IGF-I also increases 
IGFBP-3 mRNA by sixfold (Bale and Conover, 1992). In 





Fig. 2. Effects of serum on IGFBP rnRNA. RPE cells were plated at 
2 x 10' cells/cm2 for 3 d in MEM + 20% CS, rinsed in MEM 3 times, 
and then treated with the indicated concentrations of calf serum (CS). 
(A) Autoradiograph from Northern blot of IGFBP and 8-actin mRNA. 
RNA was isolated after 3 d in the indicated serum concentrations. 
Northern analysis was performed with 32P-labeled cDNA probes as 
indicated in Materials and Methods. RNA transcript sizes in kb are 
listed on the right of each autoradiograph. Autoradiographs exposed 1 
day (IGFBP-3, IGFBP-6 and p-actin). (B) Densitometric analysis of 
IGFBP-3 and IGFBP-6 mRNA. Autoradiographs from multiple expo- 
sures of the experiments shown in (A) were quantitated using relative 
OD, as described in Materials and Methods. Values are the means of 
the ratio of IGFBP mRNA relative OD to pactin relative OD, ex- 
pressed as percentage of the serum free untreated control. A and B are 
taken from one of three representative experiments. 
contrast, IGF-I has no effect on IGFBP-3 mRNA expres- 
sion in human fibroblasts (Bale and Conover, 1992; 
Martinet al., 1992b). 
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Fig. 4. Western ligand blot of RPE conditioned media after growth 
factor treatment. Cells were plated, rinsed and dosed as described in 
Fig. 3. 24 h after treatment, immediately prior to RNA isolation, 
conditioned media was collected, concentrated and Western ligand 
blots were performed as outlined in the Materials and Methods. Molec- 
ular weight markers are indicated on the left. 
The mechanism which accounts for these differential 
effects of IGF-I on IGFBP-3 gene expression remains 
unknown. While a species specific difference (human 
vs. bovine) cannot be discounted, it seems unlikely. 
Both human fibroblasts and RPE cells are responsive to 
IGF-I via type I receptors (Sara and Hall, 1990; Martin 
et al., 1991b; Leschey et al., 1990) and secrete IGFBPS 
into the media (Randolph et al., 1993; Bale and 
Conover, 1992; Martin et al., 199213) like their bovine 
counterparts (Cohick and Clemmons, 1991; Bale and 
Conover, 1992). Interestingly, different sera are used to  
maintain human and bovine fibroblasts (calf serum vs. 
fetal calf serum), suggesting a factor in fetal calf serum 
might augment the ability of IGF-I to enhance IGFBP-3 
gene expression in bovine cells. In support of this idea is 
the fact that our human RPE cells are maintained in 
calf serum. However, serum crossover experiements by 
Fig. 3. Northern analysis of IGFBP mRNA after growth factor 
treatment. RPE cells were plated at 2 x lo8 cells/cm2 for 7 days in 
MEM + 20% CS, rinsed in MEM as outlined in Materials and Meth- 
ods, and then treated with 5 pM forskolin, 5 pg/ml insulin, 10 ngiml 
PDGF, EGF, a-FGF, b-FGF, or 10 nM IGF-I. (A) Autoradiograph from 
Northern Blot of IGFBP-3, IGFBP-6 and p-actin mRNA. RNA was 
isolated 24 h after treatment. Northern analysis was performed with 
32P-labeled cDNA probes for IGFBP-3, IGFBP-6, and p-actin, as indi- 
cated in Materials and Methods. RNA transcript sizes in kb are listed 
a t  the right of each autoradiograph. Autoradiographs exposed for 1 
day (IGFBP-3), 2 days (IGFBP-6), and 1 day (p-actin). (B), (0. Densi- 
tometric analyses of IGFBP-3 (B) and IGFBP-6 (C) mRNA. Autoradio- 
graphs from multiple exposures of the experiments shown in A and a t  
least one additional experiment were quantitated using relative OD 
as described in Materials and Methods. Values are means i SEM of 
the ratio of IGFBP-3 mRNA relative OD (B) or IGFBP-6 mRNA rela- 
tive OD (C) to p-actin relative OD, expressed as percentage of serum 
free untreated control. 
INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS IN EPITHELIAL CELLS 203 
Bale and Conover (1992) (i.e., culturing human fibro- 
blasts in fetal calf serum and bovine fibroblasts in calf 
serum) did not alter the ability of IGF-I to induce 
IGFBPS mRNA in bovine fibroblasts. Further work is 
needed to understand the mechanism behind the selec- 
tive regulation of IGFBP-3 by IGF-I. 
Using ligand blot analysis, we have previously 
shown that RPE cells secrete two IGFBPs, with Mr 
estimates of 34,000 and 46,000, presumed to represent 
IGFBP-6 and -3, respectively (Flier et al., 1986). In the 
current study, IGF-I treatment of human RPE cells 
increased the media concentration of the 46,000 Mr 
band. Similar increases in IGFBP-3 in the presence of 
IGF-I have been reported in multiple cultured cell 
types, including fibroblasts (Conover, 1991; Bale and 
Conover, 1992; Martin et al., 1992b1, neuroblastoma 
cells (Neely and Rosenfeld, 1992), and breast cancer 
cells (Adamo et al., 1992). Our study suggests that 
IGF-I induced changes in the 46,000 Mr IGFBP are not 
mediated via the IGF-I receptor. First, [QAYLIIGF-I, 
an analogue with normal receptor affinity but a 
marked decreased affinity for IGFBPs, including 
IGFBP-3 (Cascieri et al., 19911, did not increase RPE 
IGFBP concentrations. In contrast, des(l-3)IGF-I, an 
analogue which retains the ability to bind the IGF-I 
receptor and IGFBP-3 (Forbes et al., 1988) (but not the 
remaining IGFBPs), increased the concentration of the 
46,000 Mr IGFBP to the same degree as IGF-I alone. 
Thus, an IGF analogue which retains the ability to bind 
IGFBP-3 mimics IGF-1’s effects. Secondly, both IGF-I 
and the IGF analogues were essentially equipotent at 
enhancing RPE cell proliferation, eliminating the pos- 
sibility that the increased concentration of the 46,000 
Mr species was simply due to an increase in cell num- 
ber. Finally, the IGF-I receptor antibody, a-IR,, did not 
block IGF-I stimulation of the 46,000 Mr IGFBP. Simi- 
larly, a-IR, did not affect the ability of des(1-3)IGF-I to 
enhance media concentrations of the 46,000 Mr IGFBP. 
Collectively, these results suggest that the IGF-I cou- 
pled increased concentration of the 46,000 Mr IGFBP, 
presumed to be IGFBP-3, is a receptor independent phe- 
nomenon. In agreement with these findings, a-IR, and 
[QAYLJIGF-I have no effect on IGF-I coupled increases 
of IGFBP-3 in human fibroblasts (Conover, 1991). 
These increases are secondary to the fact that IGF-I can 
bind to and promote the subsequent release of fibro- 
blast cell surface-associated IGFBP-3 (Martin et al., 
1992b). Future experiments directly measuring se- 
creted and cell-associated IGFBP-3 in IGF-I treated 
RPE monolayers will reveal if a similar mechanism is 
occurring in human RPE cells. 
RPE cells were grown in different concentrations of 
fetal calf serum to assess whether mitogens other than 
IGF-I could potentially enhance IGFBP-3 or IGFBP-6 
production. A twofold increase in IGFBP-3 mRNA, 
with no change in IGFBP-6 mRNA, was observed in 
20% fetal calf serum. These results led us to treat RPE 
cells with both the CAMP agonist, forskolin, as well as 
candidate growth factors known to enhance both 
IGFBP secretion and gene expression in other cell lines. 
Forskolin, platelet-derived growth factor, epidermal 
growth factor, and both acidic and basic fibroblast 
growth factor produced very modest increases in the 
secreted 34,000 Mr and 46,000 Mr proteins when com- 
pared to untreated RPE cells or RPE cells treated with 
insulin. These increases, especially in the 46,000 Mr 
protein, were small when compared to the increases 
produced by IGF-I treatment. In agreement with these 
data, fetal calf serum promotes IGFBP-3 production in 
human skin fibroblasts (Baxter and Martin, 1991). In 
these cells, not only IGF-I but also at least two other 
growth factors, epidermal growth factor and transform- 
ing growth factor+, mimic the effects of fetal calf se- 
rum (Martin and Baxter, 1991; Martin et al., 1992b). In 
Swiss 3T3 cells, several heterologous mitogens, includ- 
ing bombesin, vasopressin, platelet-derived growth fac- 
tor, and epidermal growth factor stimulate IGFBP pro- 
duction. Epidermal growth factor and acid and basic 
fibroblast growth factors enhance IGFBP-3 secretion in 
rat astroblast cultures (Loret et a1.,1991), while epider- 
mal growth factor alone enhances IGFBP synthesis in 
adult rat hepatocytes (Barreca et al., 1992). 
The exact mechanism which underlies growth factor 
coupled increases in IGFBPs remains unclear. In RPE 
cells, the cAMP agonist, forskolin, modestly increased 
IGFBP secretion but had no effect on steady-state levels 
of IGFBP mRNA. Agents which elevate intracellular 
CAMP enhance IGFBP secretion in MDA-231 and 
HEC-1B cells (Camacho-Hubner et al., 1991). Parathy- 
roid hormone, independent of IGF-I, increases IGFBP 
secretion in rat osteoblasts through a cAMP dependent 
pathway (Torring et al., 1991). cAMP also augments 
IGFBP mRNA in rat hepatoma cells (Unterman et al., 
1991). In contrast, forskolin decreases both IGFBP-3 
secretion and IGFBP-3 mRNA in porcine granulosa 
cells (Grimes et al., 19921, as well as Swiss 3T3 cells, 
where phorbol ester treatment increases IGFBP-3 
mRNA (Corps and Brown, 1991). Thus, it is unlikely 
that a final common pathway will explain growth fac- 
tor coupled changes in IGFBP secretion and gene ex- 
pression. Differences likely reflect the availability of 
growth factor receptors in different cells, the direct in- 
teraction of growth factors with IGFs or IGFBPs, or the 
fact that some growth factors likely activate transcrip- 
tion while others affect mRNA translation or stability. 
In summary, our studies suggest that IGFBP produc- 
tion and secretion in human RPE cells is regulated by 
multiple variables. Most importantly, IGF-I signifi- 
cantly enhances the secretion of the 46,000 Mr IGFBP 
via a receptor independent mechanism but has no effect 
on secretion of the 34,000 Mr IGFBP. Serum alone 
stimulates IGFBP-3 mRNA while multiple candidate 
growth factors, including IGF-I, and the cAMP agonist, 
forskolin, have no effect on IGFBP-3 o r  IGFBP-6 
mRNA. Future studies are needed to understand the 
relationship between IGFBP mRNA regulation and 
growth factor stimulated IGFBP secretion in human 
RPE cells. 
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